Objective response rate Sample Clauses

Objective response rate. (XXX) at week 12 XXX at week 12 is defined as the percentage of patients who have a week 12 visit response of CR or PR prior to any evidence of progression (as defined by RECIST 1.1) and regardless of whether the responses are confirmed or not. A visit response of CR is defined when all TL and NTL lesions present at baseline have disappeared (with the exception of lymph nodes which must be <10mm to be considered non- pathological) and no ne w lesions have developed since baseline. A visit response of PR is defined when the sum of diameters of the TLs has decreased by 30% or more compared to baseline (with no evidence of progression) and the NTLs are at least stable with no evidence of new lesions. The denominator for all response rate calculations will be based on Full analysis set.
AutoNDA by SimpleDocs
Objective response rate. (XXX) Objective response rate (XXX) as defined in section 3.2.2.1 will be reported and analyzed over the whole study and reported at week 12 in the ITT. A tabulation of response rate at 12 weeks and proportion progression free at 12 weeks will be presented for the overall population, PIK3CA detected and PIK3CA not detected. Best overall response will be presented by treatment group at time of PFS analysis. Frequencies and percentages will be presented for complete responses and partial response, stable disease, progressive disease and not evaluable. Summaries will be repeated based on the overall population, PIK3CA detected, PIK3CA not detected, PIK3CA detected (blood (ctDNA)) and PIK3CA not detected (blood (ctDNA)). Objective tumour response rates will be compared between the two treatment arms for scenarios i – iii outlined in the primary analysis above using a logistic regression model allowing for the effect of treatment and adjusted for PIK3CA mutation status in the overall population. The analysis will also be repeated based on PIK3CA mutation detected/not detected by blood (ctDNA) only. The objective tumour response rate will be estimated for each arm. If there is an imbalance in the covariates, adjusted response rates will also be presented. These are the counterparts of lsmeans from linear models and require conditioning on one arm’s observed response rate. An estimate statement would be used that weights log-odds in line with the prevalence of the covariates.

Related to Objective response rate

  • Determination of Responsiveness 28.1 The Procuring Entity's determination of a Tender's responsiveness is to be based on the contents of the Tender itself, as defined in ITT28.2.

  • Inability to Determine Rates If the Required Lenders determine that for any reason in connection with any request for a Eurodollar Rate Loan or a conversion to or continuation thereof that (a) Dollar deposits are not being offered to banks in the London interbank eurodollar market for the applicable amount and Interest Period of such Eurodollar Rate Loan, (b) adequate and reasonable means do not exist for determining the Eurodollar Rate for any requested Interest Period with respect to a proposed Eurodollar Rate Loan, or (c) the Eurodollar Rate for any requested Interest Period with respect to a proposed Eurodollar Rate Loan does not adequately and fairly reflect the cost to such Lenders of funding such Loan, the Administrative Agent will promptly so notify the Borrower and each Lender. Thereafter, the obligation of the Lenders to make or maintain Eurodollar Rate Loans shall be suspended until the Administrative Agent (upon the instruction of the Required Lenders) revokes such notice. Upon receipt of such notice, the Borrower may revoke any pending request for a Borrowing of, conversion to or continuation of Eurodollar Rate Loans or, failing that, will be deemed to have converted such request into a request for a Borrowing of Base Rate Loans in the amount specified therein.

  • Liability Calculation Method Per Claim Unless subject to a fixed dollar copayment, the calculation of Member liability on claims for Out-of-Area Covered Health Care Services processed through the BlueCard Program will be based on the lower of the provider’s billed charges or the negotiated price made available to Blue Shield by the Host Blue. Host Blues determine a negotiated price, which is reflected in the terms of each Host Blue’s health care provider contracts. The negotiated price made available to Blue Shield by the Host Blue may be represented by one of the following:

  • Additional RO Review Criteria (1) In addition to the requirements in Subparagraph 34A, the RO must:

  • Benefit Level Two Health Care Network Determination Issues regarding the health care networks for the 2017 insurance year shall be negotiated in accordance with the following procedures:

  • Deviation from Grievance Procedure The Employer agrees that, after a grievance has been discussed at Step 2 of the grievance procedure the Employer or his representatives shall not initiate any discussion or negotiations with respect to the grievance, either directly or indirectly with the aggrieved employee without the consent of the xxxxxxx or the Union.

  • Alternate or Supplemental Pricing Documents No response Optional. If when completing Pricing Form 1 & Pricing Form 2 you direct TIPS to view additional, alternate, or supplemental pricing documentation, you may upload that documentation.

  • Program Objective The objectives of the Department’s grants are to:

  • Claims Review Objective A clear statement of the objective intended to be achieved by the Claims Review.

  • INDIVIDUAL CASE BASIS PRICING 42.1. Individual Case Basis (ICB) pricing will be provided by Sprint upon request from the CLEC for customer specific rates or terms for network services and features for UNEs that are not otherwise provided for in this Agreement.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!